Axsome Therapeutics (AXSM) said Monday it received feedback from the US Food and Drug Administration supporting a submission of its drug for Alzheimer's disease agitation for approval.
Meeting minutes from the company's pre-new drug application huddle with the FDA indicated that the company's regulatory data package for AXS-05 would support a supplemental new drug application, the company said.
The company said it anticipates making such a submission in Q3.
The treatment holds the FDA's breakthrough therapy designation and will be eligible for a priority review, Axsome noted.
Price: 129.00, Change: +1.46, Percent Change: +1.14
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.